KalVista Pharmaceuticals, Inc. provides an operational update and releases financial results for the second fiscal quarter ended 31 October 2021.
“This quarter we made great strides in advancing the two distinct compounds in our oral HAE franchise into later stage trials. We are very pleased with the Phase 3 trial design for KVD900, our candidate for on-demand HAE therapy, where we believe the primary endpoint is both meaningful to patients and was successful in our Phase 2 trial. The KVD824 KOMPLETE Phase 2 protocol for prophylactic treatment of HAE has regulatory approvals in 12 of the 13 countries where the trial will be conducted,” says Andrew Crockett, CEO of KalVista. “Importantly, we are funded into at least early 2024, beyond both the KVD900 Phase 3 and KVD824 Phase 2 clinical trial data sets.”
(Source: KalVista)
